Feeds:
Posts
Comments

Archive for the ‘Novo Nordisk’ Category

For you or someone you know….

Senior Brand Manager (Princeton, NJ)

Field Sales Diabetes Care Specialist (Chicago, IL)

Field Sales Diabetes Care Specialist (Glassboro, NJ)

Senior Manager, Field Force Training (East) (West)

Read Full Post »

*****

Impactiviti has launched a new venture, and we’d like to ask for your help to make it a success! Introducing the Impactiviti Talent Network – on-line job search joined to social networking. This can help you as a job seeker, AND as a company posting openings. Check it out!

TODAY’S NEWS:

So Novo Nordisk decides to pull certain drugs from the market in Greece because the bankrupt and irresponsible government there decrees price cuts that would force Novo to lose money. And Novo is the bad guy in this?? Not on your life! I’m glad the company had the courage to take the PR hit and act like a business.

Glaxo settles more Avandia lawsuits – A company spokeswoman said on Tuesday that consolidated cases which had been due to come to court in Philadelphia this month had been settled. She declined to give further details and said the terms remained confidential. Analysts estimate Glaxo had faced a total of 13,000 claims for damages involving Avandia, of which around 5,000 were consolidated in Philadelphia, and there had been fears it could face damages of up to $6 billionmore

From Forbes: The death of the blockbuster drug.

RECOMMENDED

Negotiation Training. We’ve got the vendor/partners you need for this – as well as Speaker/Presentation training, and Coaching.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

JOB OPENINGS

Sales and Account Manager, Training Agency serving Life Sciences (Massachusetts), experience required. From the Impactiviti Job Board.

PLUS

The 10 Weirdest Drug Stories of the Month (May). From BNet.

JUST FOR FUN

From the Onion, of course. Adderall receives honorary degree from Harvard. Pretty funny! And – I’m not going to THIS Sunday roast (at least, not with the family!)

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Novartis loses this round on the big discrimination suit – A federal jury in New York reached a verdict on Monday requiring Novartis Pharmaceuticals to pay $3.36 million to 12 former female sales representatives for discrimination in pay and promotionsmore

With a sweetened bid, Astellas lands OSI Pharmaceuticals.

Novo Nordisk doing well! And continuing high market expectations for Celgene.

Glaxo‘s big bet on a new type of cardiovascular treatment.

RECOMMENDED

“Basic” Rep New Hire Training. The Impactiviti partner network has the providers you need for new hire training – from selling skills to therapeutic/product training to compliance to much more! Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Ultimate List: 300 up-to-date Social Media Statistics

JUST FOR FUN

The World’s Most Bizarre Man-Made Disasters. Maybe this isn’t “Just For Fun,” but it’s still fascinating…

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

COMING UP SOON: BDI’s Social Communications and Healthcare half-day gathering. NYC, May 11 – all details here. I will be leading a roundtable. Use discount code IMPACT for $155 registration rate.

*****

TODAY’S NEWS

Allergan – Rolling high-stakes legal dice re: Botox. Here and here.

Novo’s Victoza: nice results in comparison with Merck‘s Januvia. Plus, an experimental Januvia competitor gets dropped by Forest Labs.

Experimental once-a-day malaria drug looking really good – An experimental once-a-day malaria drug worked as well at treating the mosquito-borne illness as Novartis AG’s twice-daily pill Coartem, according to a study published today in the journal Lancetmore

RECOMMENDED

Account Management Training – Need to make your account managers more effective? Creative and successful programs are available from Impactiviti’s partner network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Surround Yourself with Smart People.

JUST FOR FUN

Serene Sunrises. 40. A visual treat.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Big change – Dan Vasella to step aside as Novartis CEO. This article also details the other internal leadership changes – very interesting.

Novo Nordisk gets approval for new diabetes drug Victoza – Federal health officials on Monday approved Danish drugmaker Novo Nordisk’s once-daily injection for treating type 2 diabetes but said more safety studies are needed before it can be cleared as a first-line treatment for the disease. The Food and Drug Administration said it approved the drug, Victoza, to help lower blood sugar levels when coupled with diet, exercise and other diabetes medicines. It was not recommended as an initial therapy for patients who have not been able to control their diabetes with diet and exercise alonemore Meanwhile, Amylin waiting for once-weekly treatment to be approved.

Will 2010 be a big year for big pharma?

No matter what, I’ll still enjoy red wine – GlaxoSmithKline shocked the pharmaceutical industry in 2008 when it dropped $720 million to buy Sirtris Pharmaceuticals, a biotechnology company working on drugs based on resveratrol, a chemical in red wine thought to combat the effects of aging. But now researchers at rival companies are openly questioning whether the compounds will work. They say they are unable to replicate key laboratory experiments backing the drugs’ promisemore

RECOMMENDED

Selling to the C-Suite – Do your sales executives need to be better prepared to sell all the way up to the C-Suite? We can help with that. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The post I keep wanting to write…but haven’t yet. Well, I finally partially wrote it….

JUST FOR FUN

Dilbert on Doing What Matters. :>}

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Some surprises in the new diabetes guidelines issue by the American Diabetes Association and European Association for the Study of Diabetes…more

Speaking of diabetes – we’re paying a lot more over the last few years!

And, a triple dose of diabetes news, including bad news for Avandia.

Medtronic exec says devices are finished?????? Now that’s an interesting PR move!

FDA accepts priority review of expanded Erbitux label.

My favorite headline of the week. Type-1 Diabetes Not So Much Bad Genes as Good Genes Behaving Badly, Stanford Research Shows.

Novo: we have cash and we know how to use it – Novo Nordisk A/S is earmarking as much as $2 billion for takeovers in the next 12 months as the financial crisis forces cash-strapped biotechnology companies onto the market, Chief Financial Officer Jesper Brandgaard said.“We are more or less able to finance in cash acquisitions within the $1 billion to $2 billion range,” Brandgaard said in a phone interview from Copenhagen. “We think there will be opportunities in biotech which we haven’t seen before.”…more

Meet the new team at Pfizer.

Ortho Clinical Diagnostics gets a biological tester approved.

Big Crestor study results could be “game changer” – A forthcoming AstraZeneca study could dramatically increase the market for cholesterol-lowering drugs, otherwise known as statins, which are already pharma’s biggest success story, Forbes writes…more

New “Superbug” antibiotics on the way? – Two experimental antibiotics appear to work safely against an increasingly common and dangerous form of infection called methicillin-resistant Staphylococcus aureus or MRSA, researchers said on Sunday…more

Schering’s new anesthesia-recovery drug looking good – An experimental drug worked many times faster than a standard treatment in helping surgery patients recover from anesthesia, according to a just-published study funded by its developer, Schering-Plough Corp…more

Lashes. Lovely lashes. And an eye-color change, too. Welcome to Lumigan.

$1.4 Billion – “not meaningful” to Eli Lilly. Huh?

Some promising Phase III clinical trial results – Novartis biologic shows great efficacy on a rare autoinflammatory disease. And, Merck‘s Isentress looks good on treatment-naive HIV patients.

Apidra approved for pediatric diabetes – Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra® (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus…more

U.S. drug sales growing much more slowly than forecast – The number crunchers at IMS Health just cut their estimate for growth of U.S. drug sales to 1% to 2% this year– way down from the 4% to 5% they’d previously forecasted, the WSJ reportsmore

BusinessWeek chats with a few pharma CEOs – As part of a package of stories about big pharma, BusinessWeek grabbed the ceo at four drugmakers – Pfizer’s Jeff Kindler; Bristol-Myers Squibb’s Jim Cornelius; Lilly’s John Lechleiter and Roche’s Severin Schwan – to discuss the varied and vexing problems the industry faces. Here are a few of their comments…more

Reblog this post [with Zemanta]

Read Full Post »

Merck the latest to make major cuts to its sales force – The unwinding of the Big Pharma sales armies continues apace, with Merck saying late today that it’s cutting its U.S. sales force by 1,200 positions, or about 14% from 8,500 reps at the start of 2007…more (and, in a strange twist, it appears that certain other layoffs were made public via Powerpoint!)

Device industry not immune either: Medtronic to make major cuts – Medtronic Inc on Tuesday said it would eliminate about 1,100 jobs this year, or almost 3 percent of its work force, in businesses whose growth has slowed, including its flagship heart rhythm device unit…more

Cephalon’s Fentora denied wider use – U.S. health officials should reject expanded use of Cephalon Inc’s Fentora pain drug beyond cancer patients because of the potential for abuse of the powerful narcotic, an advisory panel of outside experts said on Tuesday…more

King Pharma’s profitability falls as generic Altace competition ramps up – King Pharmaceuticals Inc posted a 24 percent drop in first-quarter profit on Thursday as sales of its Altace blood-pressure drug plunged due to competition from generics…more

Abbott putting focus on ADHD market – Pay attention! Abbott Laboratories wants you to get excited about its new ADHD drug, but don’t worry, it won’t keep you up all night…more

New version of Novo Seven cleared – Denmark’s Novo Nordisk won U.S. approval to sell a new formulation of a genetically engineered protein therapy that helps the blood clot, regulators said on Friday…more

Read Full Post »

Older Posts »